Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009)

Diagnostic Microbiology and Infectious Disease

Volumn 68, Issue 3, 2010, Pages 307-311

  Mendes, Rodrigo E ^a   Farrell, David J ^a   Sader, Helio S ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter spp.; Multidrug resistance; Nosocomial infections; Tigecycline

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; ASIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; EUROPE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; WESTERN HEMISPHERE;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; ASIA; CROSS INFECTION; EUROPE; HOSPITALS; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; NORTH AMERICA; POLYMYXIN B;

EID: 77957900178     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.07.003     Document Type: Article

References (18)

1. Amin A. Clinical and economic consequences of ventilator-associated pneumonia. Clin. Infect. Dis. 2009, 49(Suppl. 1):S36-S43.
2. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eight edition, M07-A8 2009, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 20th informational supplement (M100-S20) 2010, CLSI, Wayne, PA.
4. Curcio D., Fernandez F., Vergara J., Vazquez W., Luna C.M. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J. Chemother. 2009, 21:58-62.
5. Garrison M.W., Mutters R., Dowzicky M.J. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn. Microbiol. Infect. Dis. 2009, 65:288-299.
6. Herwaldt L.A., Cullen J.J., Scholz D., French P., Zimmerman M.B., Pfaller M.A., Wenzel R.P., Perl T.M. A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections. Infect. Control Hosp. Epidemiol. 2006, 27:1291-1298.
7. Higgins P.G., Dammhayn C., Hackel M., Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 2010, 65:233-238.
8. Jawad A., Seifert H., Snelling A.M., Heritage J., Hawkey P.M. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J. Clin. Microbiol. 1998, 36:1938-1941.
9. Kilgore M., Brossette S. Cost of bloodstream infections. Am. J. Infect. Control. 2008, 36(S172):e171-e173.
10. Livermore D.M. Has the era of untreatable infections arrived?. J. Antimicrob. Chemother. 2009, 64(Suppl. 1):i29-i36.
11. Livermore D.M., Hope R., Brick G., Lillie M., Reynolds R. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J. Antimicrob. Chemother. 2008, 62(Suppl. 2):ii55-ii63.
12. OXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. Antimicrob. Agents Chemother. 2009, 53:843-844.
13. Mendes R.E., Spanu T., Deshpande L., Castanheira M., Jones R.N., Fadda G. Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy. Clin. Microbiol. Infect. 2009, 15:588-592.
14. Metan G., Alp E., Yildiz O., Percin D., Aygen B., Sumerkan B. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J. Chemother. 2010, 22:110-114.
15. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., Bonomo R.A. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2007, 51:3471-3484.
16. Sader H.S., Jones R.N., Dowzicky M.J., Fritsche T.R. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 2005, 52:203-208.
17. Tacconelli E., Smith G., Hieke K., Lafuma A., Bastide P. Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates. J. Hosp. Infect. 2009, 72:97-103.
18. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004, 39:309-317.